Patents by Inventor Ian Wicks

Ian Wicks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modulating cytokine or hormone signalling in an animal comprising up-regulating the expression of SOCS sequence in the animal
    Publication number: 20080009447
    Abstract: The present invention relates generally to a method for the treatment and/or prophylaxis of conditions arising from or otherwise associated with aberrations in hormone signaling. More particularly, the present invention contemplates a method for the treatment and/or prophylaxis of conditions, the amelioration of symptoms of which, are facilitated by an over-expression of a gene encoding a suppressor of cytokine signaling molecule. The present invention further contemplates agents useful for the prophylaxis and/or treatment of such conditions in mammals including humans.
    Type: Application
    Filed: July 9, 2007
    Publication date: January 10, 2008
    Applicant: Amrad Operations Pty Ltd
    Inventors: Andrew Nash, Pino Maccarone, Paul Egan, Ian Wicks
  • Method of treatment and prophylaxis
    Publication number: 20060093604
    Abstract: The present invention relates generally to a method for treating or preventing or otherwise ameliorating the effects of inflammatory conditions such as but not limited to chronic immune-mediated inflammatory diseases. The present invention further provides pharmaceutical compositions comprising agents which inhibit one or more inflammatory cytokines and/or which down-regulate expression of genes which encode inflammatory cytokines. Such compositions are useful in the treatment and prophylaxis of inflammatory conditions such as inflammatory arthritis amongst other chronic immune-mediated inflammatory diseases. The present invention further provides an animal model for studying the kinetics of and/or screening for agents useful in the treatment or prophylaxis of inflammatory conditions.
    Type: Application
    Filed: August 22, 2003
    Publication date: May 4, 2006
    Applicant: The Walter and Eliza Hall Institute of Medical Research
    Inventors: Kathryn Lawlor, Ian Wicks, Ian Campell, Andrew Roberts, Donald Metcalf
  • Modulating cytokine or hormone signalling in an animal comprising up-regulating the expression of socs sequence in the animal
    Publication number: 20040072752
    Abstract: The present invention relates generally to a method for the treatment and/or prophylaxis of conditions arising from or otherwise associated with aberrations in hormone signalling. More particularly, the present invention contemplates a method for the treatment and/or prophylaxis of conditions, the amelioration of symptoms of which, are facilitated by an over-expression of a gene encoding a suppressor of cytokine signalling molecule. The present invention further contemplates agents useful for the prophylaxis and/or treatment of such renditions in mammals including humans.
    Type: Application
    Filed: August 29, 2003
    Publication date: April 15, 2004
    Inventors: Andrew Nash, Pino Maccarone, Paul Egan, Ian Wicks
  • Method for screening for soluble ligands to a receptor-type tyrosine kinase
    Patent number: 6599709
    Abstract: The present invention relates to a method of screening for ligands to a receptor-type tyrosine kinase. The receptor-type tyrosine, in its naturally occurring form, is characterized by being reactive to monoclonal antibody III.A4, having an apparent molecular weight of approximately 120-150 kD in its glycosylated form, and having the N-terminal amino acid sequence E L I P Q P.
    Type: Grant
    Filed: November 18, 1999
    Date of Patent: July 29, 2003
    Assignee: The Walter and Eliza Hall Institute of Medical Research
    Inventors: Andrew W. Boyd, Richard Simpson, Ian Wicks, Larry David Ward, David Wilkinson
  • Receptor-type tyrosine kinase and use thereof
    Patent number: 6020306
    Abstract: The present invention relates to an isolated receptor-type tyrosine kinase. The receptor-type tyrosine, in its naturally occurring form, is characterized by being reactive to monoclonal antibody III.A4, having an apparent molecular weight of approximately 120-150 kD in its glycosylated form, and having the N-terminal amino acid sequence E L I P Q P.
    Type: Grant
    Filed: September 18, 1996
    Date of Patent: February 1, 2000
    Assignee: Amrad Corporation Limited
    Inventors: Andrew W. Boyd, Richard Simpson, Ian Wicks, Larry David Ward, David Wilkinson
  • Method of screening for ligands to a receptor-type tyrosine kinase
    Patent number: 5674691
    Abstract: The present invention relates to a method of screening for ligands to a receptor-type tyrosine kinase. The receptor-type tyrosine, in its naturally occurring form, is characterized by being reactive to monoclonal antibody III.A4, having an apparent molecular weight of approximately 120-150 kD in its glycosylated form, and having the N-terminal amino acid sequence E L I P Q P.
    Type: Grant
    Filed: April 18, 1994
    Date of Patent: October 7, 1997
    Assignee: Amrad Corporation Limited
    Inventors: Andrew W. Boyd, Richard John Simpson, Ian Wicks, Larry David Ward, David Wilkinson